Ignacio Matos
YOU?
Author Swipe
View article: Hematological values in healthy adult mixed-breed male dogs (Canis lupus familiaris Linnaeus, 1758) from Rolim de Moura city, Rondônia state – preliminary study
Hematological values in healthy adult mixed-breed male dogs (Canis lupus familiaris Linnaeus, 1758) from Rolim de Moura city, Rondônia state – preliminary study Open
For the correct interpretation of complete blood counts (CBCs), standardization is required according to species, age, sex, breed, and especially geographic location, since geoclimatic conditions directly influence hematological parameters…
View article: MAIN NEONATAL HARMS ASSOCIATED WITH CESAREAN: A INTEGRATIVE REVIEW
MAIN NEONATAL HARMS ASSOCIATED WITH CESAREAN: A INTEGRATIVE REVIEW Open
Introduction :The Cesarean Section is a medical procedure widely utilized. Originally, it was conceived as a last-resort intervention to save the life of the mother or fetus in critical situations. Over the years, however, it has become an…
View article: Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry Open
Background Emerging evidence has demonstrated rare subacute to late neurological toxicities (NTs) after BCMA CAR T-cell therapy (CAR-T) in multiple myeloma (MM). These adverse events can be categorized as: 1) Parkinsonism (PD), 2) cranial …
View article: Immigrant Health and Early-Onset Colorectal Cancer Disparities: Results From the Spanish Early-Onset Colorectal Cancer Consortium
Immigrant Health and Early-Onset Colorectal Cancer Disparities: Results From the Spanish Early-Onset Colorectal Cancer Consortium Open
PURPOSE To better understand immigration disparities among a Spanish Early-Onset Colorectal Cancer (SECOC) subset, according to the country of origin. PATIENTS AND METHODS We selected 250 consecutive participants from the SECOC consortium.…
View article: Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers
Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers Open
Colorectal cancer remains the second most common cause of cancer-related death in Western countries in terms of incidence and mortality, and is the most common tumour type in both sexes1. Up to 10% of all patients with colorectal cancer ar…
View article: Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis
Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis Open
Background Neoadjuvant chemotherapy is increasingly used to treat locally advanced (T3–4 Nx–2 M0) colon cancer due to its potential advantages over the standard approach of upfront surgery. The primary objective of this systematic review a…
View article: Fcγ receptors and immunomodulatory antibodies in cancer
Fcγ receptors and immunomodulatory antibodies in cancer Open
The discovery of both cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to the development of numerous immunomodulatory antibodies as cancer trea…
View article: Supplementary Figures S1-S15 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Figures S1-S15 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Supplementary Figure 1. Validation of HLA-I ligand tumor antigen candidates with synthetic peptidesSupplementary Figure 2. Validation of selected HLA-I ligand tumor antigen candidates identified in Mel-1 and Mel-3 with isotope-labeled pept…
View article: Supplementary Table S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Table S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Show patient characteristics and relevant experimental information
View article: Data from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Data from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Purpose:Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated the immunogenicity of …
View article: Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Includes the list of peptides derived from NSM identified at 0.02 FDR and ALC>=30
View article: Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Includes a large list of all the peptides and details of the HLA-I ligands identified at =30 ALC score
View article: Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Includes the list of peptides derived from NSM identified at 0.02 FDR and ALC>=30
View article: Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Includes a large list of all the peptides and details of the HLA-I ligands identified at =30 ALC score
View article: Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Tumor cell line HLA-I typing and tumor type
View article: Supplementary Figures S1-S15 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Figures S1-S15 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Supplementary Figure 1. Validation of HLA-I ligand tumor antigen candidates with synthetic peptidesSupplementary Figure 2. Validation of selected HLA-I ligand tumor antigen candidates identified in Mel-1 and Mel-3 with isotope-labeled pept…
View article: Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Tumor cell line HLA-I typing and tumor type
View article: Supplementary Table S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Table S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Show patient characteristics and relevant experimental information
View article: Supplementary Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
Supplementary Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial Open
Table 1: samples included in the RNAseq analysis Figure 1: consort flow diagram Table 2: Comparison of patients' characteristics of the subset of patients included in the RNA-seq analysis and patients recruited in the DECISION study Figure…
View article: Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial Open
Several biomarkers have been suggested to have prognostic value in differentiated thyroid carcinomas (DTC) with no validation in the refractory setting, including all tumor subtypes. We aim to correlate RNA expression profiles with surviva…
View article: Supplementary Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
Supplementary Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial Open
Table 1: samples included in the RNAseq analysis Figure 1: consort flow diagram Table 2: Comparison of patients' characteristics of the subset of patients included in the RNA-seq analysis and patients recruited in the DECISION study Figure…
View article: Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial Open
Several biomarkers have been suggested to have prognostic value in differentiated thyroid carcinomas (DTC) with no validation in the refractory setting, including all tumor subtypes. We aim to correlate RNA expression profiles with surviva…
View article: Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Includes the list of peptides derived from NSM identified at 0.02 FDR and ALC>=30
View article: Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Includes a large list of all the peptides and details of the HLA-I ligands identified at =30 ALC score
View article: Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Includes a large list of all the peptides and details of the HLA-I ligands identified at =30 ALC score
View article: Supplementary Figures S1-S15 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Figures S1-S15 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Supplementary Figure 1. Validation of HLA-I ligand tumor antigen candidates with synthetic peptides Supplementary Figure 2. Validation of selected HLA-I ligand tumor antigen candidates identified in Mel-1 and Mel-3 with isotope-labeled pep…
View article: Supplementary Table S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Table S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Show patient characteristics and relevant experimental information
View article: Data from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Data from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Purpose:Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated the immunogenicity of …
View article: Data from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Data from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Purpose:Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated the immunogenicity of …
View article: Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics Open
Includes the list of peptides derived from NSM identified at 0.02 FDR and ALC>=30